Table of Contents
Chapter 1. Global Duchenne Muscular Dystrophy Market Executive Summary
1.1. Global Duchenne Muscular Dystrophy Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Therapeutic Area
1.3.2. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Duchenne Muscular Dystrophy Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Duchenne Muscular Dystrophy Market Dynamics
3.1. Market Drivers
3.1.1. Rising incidence of Duchenne muscular dystrophy
3.1.2. Advancements in genetic research and therapies
3.1.3. Increasing healthcare infrastructure investments
3.2. Market Challenges
3.2.1. High cost of treatments
3.3. Market Opportunities
3.3.1. Growing demand for advanced healthcare services
3.3.2. Government spending on pharmaceutical and biotechnology sectors
3.3.3. Development of innovative treatments
Chapter 4. Global Duchenne Muscular Dystrophy Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Duchenne Muscular Dystrophy Market Size & Forecasts by Therapeutic Area 2022-2032
5.1. Molecular-Based Therapies Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2. Steroid Therapy Revenue Trend Analysis, 2022 & 2032 (USD Billion)
Chapter 6. Global Duchenne Muscular Dystrophy Market Size & Forecasts by Distribution Channel 2022-2032
6.1. Hospital Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2. Drug Store & Retail Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.3. Online Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Billion)
Chapter 7. Global Duchenne Muscular Dystrophy Market Size & Forecasts by Region 2022-2032
7.1. North America Duchenne Muscular Dystrophy Market
7.1.1. U.S. Duchenne Muscular Dystrophy Market
7.1.1.1. Therapeutic Area breakdown size & forecasts, 2022-2032
7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
7.1.2. Canada Duchenne Muscular Dystrophy Market
7.2. Europe Duchenne Muscular Dystrophy Market
7.2.1. U.K. Duchenne Muscular Dystrophy Market
7.2.2. Germany Duchenne Muscular Dystrophy Market
7.2.3. France Duchenne Muscular Dystrophy Market
7.2.4. Spain Duchenne Muscular Dystrophy Market
7.2.5. Italy Duchenne Muscular Dystrophy Market
7.2.6. Rest of Europe Duchenne Muscular Dystrophy Market
7.3. Asia-Pacific Duchenne Muscular Dystrophy Market
7.3.1. China Duchenne Muscular Dystrophy Market
7.3.2. India Duchenne Muscular Dystrophy Market
7.3.3. Japan Duchenne Muscular Dystrophy Market
7.3.4. Australia Duchenne Muscular Dystrophy Market
7.3.5. South Korea Duchenne Muscular Dystrophy Market
7.3.6. Rest of Asia Pacific Duchenne Muscular Dystrophy Market
7.4. Latin America Duchenne Muscular Dystrophy Market
7.4.1. Brazil Duchenne Muscular Dystrophy Market
7.4.2. Mexico Duchenne Muscular Dystrophy Market
7.4.3. Rest of Latin America Duchenne Muscular Dystrophy Market
7.5. Middle East & Africa Duchenne Muscular Dystrophy Market
7.5.1. Saudi Arabia Duchenne Muscular Dystrophy Market
7.5.2. South Africa Duchenne Muscular Dystrophy Market
7.5.3. Rest of Middle East & Africa Duchenne Muscular Dystrophy Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. F Hoffmann-La Roche AG
8.1.2. GlaxoSmithKline plc
8.1.3. Pfizer Inc.
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. FibroGen, Inc.
8.3.2. Italfarmaco S.p.A.
8.3.3. Nippon Shinyaku Co., Ltd
8.3.4. PTC Therapeutics
8.3.5. Santhera Pharmaceuticals Inc
8.3.6. Sarepta Therapeutics
8.3.7. Wave Life Sciences Ltd.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes